Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of different atorvastatin doses on lipoprotein(a) and cardiovascular events after PCI in ACS
ChiCTR2100053739Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atorvastatin in acute coronary syndrome (ACS) (2 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: Lipoprotein(a) levels at 1 year. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2100053739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053739.